On September 18, 2025, Canada’s Drug Agency (CDA) launched its new strategy to improve the appropriate prescribing and use of prescription medications in Canada. The strategy, titled “A Prescription for Action: A Pan-Canadian Strategy for Advancing the Appropriate Use of Prescription Medications,” provides a 5-year plan to foster a unified national approach that promotes safer, more effective medication use and strengthens health system sustainability.
The strategy sets out four strategic priorities:
- Partnerships and Program Development: Develop, enhance, and implement appropriate use initiatives with partners across Canada.
- Connect: Strengthen networks and provide comprehensive information about appropriate use.
- Strategy and Policy: Develop evidence-informed advice and recommendations for decision-makers about the adoption and implementation of appropriate use policies and strategic initiatives.
- Evaluation and Reporting: Assess project outcomes and communicate impact clearly.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada’s Drug Agency announces consultation on streamlined review process and new reconsideration/resubmission procedures
On January 29, 2026, Canada’s Drug Agency (CDA) published Improvements to the Drug Reimbursement Review Process, which includes a section for consultation on proposed changes to the reimbursement re...Read More -
PMPRB consults on proposed Practice Directions for PMPRB hearings
The Patented Medicine Prices Review Board (PMPRB) holds public hearings in two types of matters: to determine whether the price of a medicine is excessive; and to determine whether a rights holder ha...Read More -
Canada announces new Pharmaceutical and Life Sciences Sector Task Force
On March 18, 2026, the federal Minister of Health announced the creation of the Pharmaceutical and Life Sciences Sector Task Force, a joint initiative led by Health Canada and Innovation, Science and ...Read More
